{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:01:56Z","timestamp":1786539716020,"version":"build-2736575974"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ahram Canadian University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This study explores the antimicrobial resistance patterns and virulence properties of\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    obtained from blood samples of febrile immunocompromised patients. Fifty-two clinical isolates were examined for demographic and clinical characteristics, antimicrobial resistance profiles, and different virulence factors. Antimicrobial susceptibility testing and qualitative detection of efflux pump activity, biofilm formation, pigment production, and swarming motility were evaluated. The pathogenic potential of the isolates was assessed using the\n                    <jats:italic>Galleria mellonella<\/jats:italic>\n                    infection model. All isolates exhibited MDR, XDR, and PDR phenotypes. The crude 30-day mortality rate was 26.9%, with higher mortality detected in infections due to XDR strains. Colistin, aztreonam, and ceftolozane\/tazobactam demonstrated the best susceptibility rates. Metallo-\u03b2-lactamase\n                    <jats:sub>\n                      <jats:italic>NDM\u22121<\/jats:italic>\n                    <\/jats:sub>\n                    was the most frequently detected gene in our isolates. Efflux pump activity was significantly associated with higher MICs. Biofilm formation was predominant, with moderate to strong biofilm formers showing reduced antibiotic susceptibility. Swarming motility is associated with urinary tract infections. The\n                    <jats:italic>Galleria mellonella<\/jats:italic>\n                    model demonstrated higher lethality for isolates originating from respiratory tract infections. This study highlights the escalating load of antimicrobial resistance and significant virulence of\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    which directly affects the available treatment strategies. The use of the relatively novel ceftolozane\/tazobactam combination is threatened due to the high levels of\n                    <jats:italic>bla<\/jats:italic>\n                    <jats:sub>NDM\u22121<\/jats:sub>\n                    producers detected. Colistin and Aztreonam are still offered treatment options.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Clinical trial number<\/jats:bold>\n                    : Not applicable.\n                  <\/jats:p>","DOI":"10.1186\/s12879-025-11182-0","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T05:57:07Z","timestamp":1749621427000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Multidrug-resistant Pseudomonas aeruginosa in immunocompromised cancer patients: epidemiology, antimicrobial resistance, and virulence factors"],"prefix":"10.1186","volume":"25","author":[{"given":"Asmaa","family":"Abdulhak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamdallah H.","family":"Zedan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadir A.","family":"El-Mahallawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hend O.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4507-376X","authenticated-orcid":false,"given":"Mai M.","family":"Zafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"issue":"4","key":"11182_CR1","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3390\/microorganisms12040705","volume":"12","author":"C Royo-Cebrecos","year":"2024","unstructured":"Royo-Cebrecos C, Laporte-Amarg\u00f3s J, Pe\u00f1a M, Ruiz-Camps I, Garcia-Vidal C, Abdala E, et al. Pseudomonas aeruginosa bloodstream infections presenting with septic shock in neutropenic Cancer patients: impact of empirical antibiotic therapy. Microorganisms. 2024;12(4):705.","journal-title":"Microorganisms"},{"issue":"3","key":"11182_CR2","doi-asserted-by":"publisher","first-page":"e02292","DOI":"10.1128\/spectrum.02292-21","volume":"10","author":"A Bergas","year":"2022","unstructured":"Bergas A, Albasanz-Puig A, Fern\u00e1ndez-Cruz A, Machado M, Novo A, van Duin D, et al. Real-Life use of ceftolozane\/tazobactam for the treatment of bloodstream infection due to Pseudomonas aeruginosa in neutropenic hematologic patients: a matched control study (ZENITH study). Microbiol Spectr. 2022;10(3):e02292\u201321.","journal-title":"Microbiol Spectr"},{"key":"11182_CR3","doi-asserted-by":"publisher","first-page":"1294141","DOI":"10.3389\/fpubh.2023.1294141","volume":"11","author":"S Xiao","year":"2023","unstructured":"Xiao S, Liang X, Han L, Zhao S. Incidence, antimicrobial resistance and mortality of Pseudomonas aeruginosa bloodstream infections among hospitalized patients in china: a retrospective observational multicenter cohort study from 2017 to 2021. Front Public Heal. 2023;11:1294141.","journal-title":"Front Public Heal"},{"key":"11182_CR4","doi-asserted-by":"publisher","unstructured":"Chen J, Huang H, Liu C, Fu Y. qiang. Risk factors for mortality in pseudomonas aeruginosa bacteremia in children. Pediatr Neonatol. 2024;65(1):31\u20137. Available from: https:\/\/doi.org\/10.1016\/j.pedneo.2023.03.012","DOI":"10.1016\/j.pedneo.2023.03.012"},{"key":"11182_CR5","unstructured":"Institute for Health Metrics and Evaluations. University of Oxford. MICROBE. 2022. Available from: https:\/\/vizhub.healthdata.org\/microbe(link is external)."},{"key":"11182_CR6","doi-asserted-by":"publisher","unstructured":"Ugwuanyi FC, Ajayi A, Ojo DA, Adeleye AI, Smith SI. Evaluation of efflux pump activity and biofilm formation in multidrug resistant clinical isolates of Pseudomonas aeruginosa isolated from a Federal Medical Center in Nigeria. Ann Clin Microbiol Antimicrob. 2021;20(1):1\u20137. Available from: https:\/\/doi.org\/10.1186\/s12941-021-00417-y","DOI":"10.1186\/s12941-021-00417-y"},{"key":"11182_CR7","doi-asserted-by":"publisher","unstructured":"Paprocka P, Durna\u015b B, Ma\u0144kowska A, Kr\u00f3l G, Wollny T, Bucki R. Pseudomonas aeruginosa Infections in Cancer Patients. Pathog MDPI. 2022;1\u201317. Available from: https:\/\/doi.org\/10.3390\/pathogens11060679","DOI":"10.3390\/pathogens11060679"},{"key":"11182_CR8","doi-asserted-by":"publisher","unstructured":"Edward EA, El Shehawy MR, Abouelfetouh A, Aboulmagd E. Prevalence of different virulence factors and their association with antimicrobial resistance among Pseudomonas aeruginosa clinical isolates from Egypt. BMC Microbiol. 2023;23(1):1\u201313. Available from: https:\/\/doi.org\/10.1186\/s12866-023-02897-8","DOI":"10.1186\/s12866-023-02897-8"},{"key":"11182_CR9","doi-asserted-by":"publisher","unstructured":"Qin S, Xiao W, Zhou C, Pu Q, Deng X, Lan L et al. Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. Signal Transduct Target Ther. 2022;7(1):199. Available from: https:\/\/doi.org\/10.1038\/s41392-022-01056-1","DOI":"10.1038\/s41392-022-01056-1"},{"key":"11182_CR10","doi-asserted-by":"crossref","unstructured":"Tuon FF, Dantas LR, Suss PH, Tasca Ribeiro VS. Pathogenesis of the Pseudomonas aeruginosa biofilm: A review. Pathog (Basel Switzerland). 2022;11(3).","DOI":"10.3390\/pathogens11030300"},{"issue":"3","key":"11182_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11274-024-03889-0","volume":"40","author":"SB Mudaliar","year":"2024","unstructured":"Mudaliar SB, Bharath Prasad AS. A biomedical perspective of pyocyanin from Pseudomonas aeruginosa: its applications and challenges. World J Microbiol Biotechnol. 2024;40(3):90.","journal-title":"World J Microbiol Biotechnol"},{"issue":"12","key":"11182_CR12","doi-asserted-by":"publisher","first-page":"e0243418","DOI":"10.1371\/journal.pone.0243418","volume":"15","author":"RM Abd El-Baky","year":"2020","unstructured":"Abd El-Baky RM, Mandour SA, Ahmed EF, Hashem ZS, Sandle T, Mohamed DS. Virulence profiles of some Pseudomonas aeruginosa clinical isolates and their association with the suppression of Candida growth in polymicrobial infections. PLoS ONE. 2020;15(12):e0243418.","journal-title":"PLoS ONE"},{"key":"11182_CR13","unstructured":"EUCAST. European Committee on Antimicrobial Susceptibility. Testing Breakpoint tables for interpretation of MICs and zone diameters. 2022;v. 12.0, v. Available from: https:\/\/www.eucast.org\/"},{"key":"11182_CR14","doi-asserted-by":"publisher","unstructured":"Magiorakos A, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2011;18(3):268\u201381. Available from: https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03570.x","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"11182_CR15","doi-asserted-by":"publisher","unstructured":"Coyne AJK. Therapeutic Strategies for Emerging Multidrug- Resistant Pseudomonas aeruginosa. Infect Dis Ther. 2022;11(2):661\u201382. Available from: https:\/\/doi.org\/10.1007\/s40121-022-00591-2","DOI":"10.1007\/s40121-022-00591-2"},{"issue":"June","key":"11182_CR16","doi-asserted-by":"publisher","first-page":"870354","DOI":"10.3389\/fpubh.2022.870354","volume":"10","author":"G Rameshkumar","year":"2022","unstructured":"Rameshkumar G, Dhandapani R, Lalitha P, Rajapandian SGK, Palanivel V, Thangavelu S, et al. Prevalence and molecular characterization of Metallo \u03b2-Lactamase producing Gram-Negative pathogens causing eye infections. Front Public Heal. 2022;10(June):870354.","journal-title":"Front Public Heal"},{"key":"11182_CR17","doi-asserted-by":"publisher","unstructured":"Sadek M, Bouvier M, Kerbol A, Poirel L, Nordmann P. Evaluation of novel immunological rapid test (K.N.I.V.O. Detection K-Set) for rapid detection of carbapenemase producers in multidrug-resistant gram negatives. Diagn Microbiol Infect Dis. 2022;104(4):115761. Available from: https:\/\/doi.org\/10.1016\/j.diagmicrobio.2022.115761","DOI":"10.1016\/j.diagmicrobio.2022.115761"},{"key":"11182_CR18","doi-asserted-by":"publisher","unstructured":"Kothari A, Kumar SK, Singh V, Kumar P, Kaushal K, Pandey A et al. Association of multidrug resistance behavior of clinical Pseudomonas aeruginosa to pigment coloration. Eur J Med Res. 2022;27(1):1\u201313. Available from: https:\/\/doi.org\/10.1186\/s40001-022-00752-6","DOI":"10.1186\/s40001-022-00752-6"},{"issue":"September","key":"11182_CR19","doi-asserted-by":"publisher","first-page":"716627","DOI":"10.3389\/fmicb.2021.716627","volume":"12","author":"MM Sherif","year":"2021","unstructured":"Sherif MM, Elkhatib WF, Khalaf WS, Elleboudy NS. Multidrug resistant Acinetobacter baumannii biofilms: evaluation of Phenotypic\u2013 Genotypic association and susceptibility to cinnamic and Gallic acids. Front Microbiol. 2021;12(September):716627.","journal-title":"Front Microbiol"},{"key":"11182_CR20","first-page":"1","volume":"20","author":"B Alonso","year":"2020","unstructured":"Alonso B, Fern\u00e1ndez-barat L, Gino E, Domenico D, Mar\u00edn M, Cercenado E. Characterization of the virulence of Pseudomonas aeruginosa strains causing ventilator-associated pneumonia. BMC Infect Dis. 2020;20:1\u20138.","journal-title":"BMC Infect Dis"},{"key":"11182_CR21","doi-asserted-by":"crossref","unstructured":"Ha D-G, Kuchma SL. and GAO. Plate-based assay for swimming motility in Pseudomonas aeruginos.pseudomonas methods and protocols. Springer 2014;59\u201365.","DOI":"10.1007\/978-1-4939-0473-0_7"},{"issue":"September","key":"11182_CR22","first-page":"1","volume":"15","author":"R Buxton","year":"2005","unstructured":"Buxton R. Blood agar plates and hemolysis protocols. Am Soc Microbiol. 2005;15(September):1\u20139.","journal-title":"Am Soc Microbiol"},{"key":"11182_CR23","unstructured":"Hak AA, Zedan HH, El-mahallawy HA, El-sayyad GS. In Vivo and in Vitro activity of colistin- conjugated bimetallic silver-copper oxide nanoparticles against Pandrug-resistant Pseudomonas aeruginosa. 2024;1\u201317."},{"key":"11182_CR24","doi-asserted-by":"publisher","unstructured":"Admella J, Torrents E. Investigating bacterial infections in Galleria mellonella larvae: Insights into pathogen dissemination and behavior. J Invertebr Pathol. 2023;200(August):107975. Available from: https:\/\/doi.org\/10.1016\/j.jip.2023.107975","DOI":"10.1016\/j.jip.2023.107975"},{"key":"11182_CR25","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/978-1-4939-0473-0_52","volume":"1149","author":"G Koch","year":"2014","unstructured":"Koch G, Nadal-Jimenez P, Cool RH, Quax WJ. Assessing Pseudomonas virulence with nonmammalian host: galleria Mellonella. Methods Mol Biol. 2014;1149:681\u20138.","journal-title":"Methods Mol Biol"},{"key":"11182_CR26","unstructured":"Field A. Discovering statistics using IBM SPSS statistics. SAGE 2013."},{"key":"11182_CR27","volume-title":"IBM SPSS statistics for windows","author":"IBM Corp","year":"2015","unstructured":"IBM Corp. IBM SPSS statistics for windows. Armonk, NY: IBM Corp 2015."},{"key":"11182_CR28","unstructured":"R Core Team. A Language and environment for statistical computing. Vienna, Austria. R Foundation for Statistical Computing 2013."},{"key":"11182_CR29","doi-asserted-by":"publisher","unstructured":"Zhao Y, Lin Q, Liu L, Ma R, Chen J, Shen Y et al. Risk Factors and Outcomes of Antibiotic-resistant Pseudomonas aeruginosa Bloodstream Infection in Adult Patients With Acute Leukemia. Clin Infect Dis. 2020;71(Supplement_4):S386\u201393. Available from: https:\/\/doi.org\/10.1093\/cid\/ciaa1522","DOI":"10.1093\/cid\/ciaa1522"},{"key":"11182_CR30","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jgar.2024.03.018","volume":"37","author":"F Yuan","year":"2024","unstructured":"Yuan F, Li M, Wang X, Fu Y. Journal of global antimicrobial resistance risk factors and mortality of carbapenem-resistant Pseudomonas aeruginosa bloodstream infection in haematology department: A 10-year retrospective study. J Glob Antimicrob. 2024;37:150\u20136.","journal-title":"J Glob Antimicrob"},{"key":"11182_CR31","doi-asserted-by":"publisher","unstructured":"Recio R, Manche\u00f1o M, Viedma EV, Orellana J, Lora-Tamayo M\u00c1. J CF. Predictors of mortality in bloodstream infections caused by Pseudomonas aeruginosa and impact of antimicrobial resistance and bacterial virulence. Antimicrob Agents Chemother. 2020;(64:e.):01759\u201319. Available from: https:\/\/doi.org\/10.1128\/AAC.01759-19","DOI":"10.1128\/AAC.01759-19"},{"issue":"1","key":"11182_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42269-020-00350-8","volume":"44","author":"AM Basha","year":"2020","unstructured":"Basha AM, El-Sherbiny GM, Mabrouk MI. Phenotypic characterization of the Egyptian isolates extensively drug-resistant Pseudomonas aeruginosa and detection of their metallo-\u03b2-lactamases encoding genes. Bull Natl Res Cent. 2020;44(1):1\u201311.","journal-title":"Bull Natl Res Cent"},{"key":"11182_CR33","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.2147\/IDR.S298920","volume":"14","author":"A El-Kholy","year":"2021","unstructured":"El-Kholy A, El-Mahallawy HA, Elsharnouby N, Aziz MA, Helmy AM, Kotb R. Landscape of multidrug-resistant gram-negative infections in egypt: survey and literature review. Infect Drug Resist. 2021;14:1905\u201320.","journal-title":"Infect Drug Resist"},{"issue":"1","key":"11182_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.21608\/jesj.2022.143610.1020","volume":"27","author":"M Mohamed","year":"2022","unstructured":"Mohamed M, Mohamed H, Afifi M. Prevalence of MDR Pseudomonas aeruginosa in intensive care units and burned patients. J Environ Stud. 2022;27(1):10\u20135.","journal-title":"J Environ Stud"},{"key":"11182_CR35","doi-asserted-by":"publisher","unstructured":"Aya M, Raafat AON, Soliman ST, Mahmoud HM, Tawfik AE, El AT et al. Analysis of cumulative antibiogram reports in intensive care units at an Egyptian University Hospital. J Infect Public Health. 2023;16(8):1220\u20139. Available from: https:\/\/doi.org\/10.1016\/j.jiph.2023.05.032","DOI":"10.1016\/j.jiph.2023.05.032"},{"key":"11182_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43168-021-00059-w","volume":"15","author":"EM Negm","year":"2021","unstructured":"Negm EM, Mowafy SMS, Mohammed AA, Amer MG, Tawfik AE, Ibrahim AES, et al. Antibiograms of intensive care units at an Egyptian tertiary care hospital. Egypt J Bronchol. 2021;15:1\u201315.","journal-title":"Egypt J Bronchol"},{"key":"11182_CR37","doi-asserted-by":"publisher","unstructured":"Karlowsky JA, Lob SH, Bauer KA, Esterly J, Siddiqui F, Young K et al. Activity of ceftolozane\/tazobactam, imipenem\/relebactam and ceftazidime\/avibactam against clinical Gram-negative isolates\u2014SMART United States 2019\u201321. JAC-Antimicrobial Resist. 2024;6(1):152. Available from: https:\/\/doi.org\/10.1093\/jacamr\/dlad152","DOI":"10.1093\/jacamr\/dlad152"},{"key":"11182_CR38","doi-asserted-by":"publisher","first-page":"1347521","DOI":"10.3389\/fmicb.2024.1347521","volume":"15","author":"D Mendes Pedro","year":"2024","unstructured":"Mendes Pedro D, Paulo SE, Santos CM, Fonseca AB, Melo Cristino J, Pereira \u00c1A, et al. Extensively drug-resistant Pseudomonas aeruginosa: clinical features and treatment with ceftazidime\/avibactam and ceftolozane\/tazobactam in a tertiary care university hospital center in Portugal - A cross-sectional and retrospective observational study. Front Microbiol. 2024;15:1347521.","journal-title":"Front Microbiol"},{"issue":"2","key":"11182_CR39","first-page":"745","volume":"5","author":"AM Elbrolosy","year":"2024","unstructured":"Elbrolosy AM, Ahmed N, Eissa AE, El- NAE, Ayman E, Eldeen H, et al. ceftazidime-avibactam plus Aztreonam combination: upcoming hope for hospital-acquired MDR \/ XDR Pseudomonas aeruginosa infections. Int J Antimicrob Agents. 2024;5(2):745\u201358.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"11182_CR40","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/jac\/dkae089","volume":"79","author":"A Fouad","year":"2024","unstructured":"Fouad A, Nicolau SE, Tamma PD, Simner PJ, Nicolau DP, Gill CM. Assessing the impact of meropenem exposure on ceftolozane\/tazobactam-resistance development in Pseudomonas aeruginosa using in vitro serial passage. J Antimicrob Chemother. 2024;79(5):1176\u201381.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"11182_CR41","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3855\/jidc.9936","volume":"12","author":"MR Raouf","year":"2018","unstructured":"Raouf MR, Sayed M, Rizk HA, Hassuna NA. Original Article high incidence of MBL-mediated Imipenem resistance among Pseudomonas aeruginosa from surgical site infections in Egypt. J Infect Dev Ctries. 2018;12(7):520\u20135.","journal-title":"J Infect Dev Ctries"},{"issue":"4","key":"11182_CR42","doi-asserted-by":"publisher","first-page":"238","DOI":"10.21608\/aprh.2022.142365.1177","volume":"0547","author":"A Azzam","year":"2022","unstructured":"Azzam A, Khaled H, Hesham M. The prevalence of Metallo- \u03b2 -Lactamase-Producing Pseudomonas aeruginosa in egypt: A systematic review and Meta-Analysis. J Adv Pharm Res. 2022;0547(4):238\u201348.","journal-title":"J Adv Pharm Res"},{"key":"11182_CR43","doi-asserted-by":"publisher","unstructured":"Wang W, Wang X. Prevalence of metallo-\u03b2-lactamase genes among Pseudomonas aeruginosa isolated from various clinical samples in China. J Lab Med. 2020;44(4):197\u2013203. Available from: https:\/\/doi.org\/10.1515\/labmed-2019-0162","DOI":"10.1515\/labmed-2019-0162"},{"key":"11182_CR44","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.3390\/microorganisms11092366","volume":"11","author":"P Antonny","year":"2023","unstructured":"Antonny P, Dos S, Jess M, Isabel M, Gouveia M, Nepomuceno L, et al. The prevalence of Metallo-Beta-Lactamese- (M \u03b2 L) -Producing Pseudomonas aeruginosa isolates in brazil: A systematic review and Meta-Analysis. Microorganisms-MDPI. 2023;11:2366.","journal-title":"Microorganisms-MDPI"},{"key":"11182_CR45","doi-asserted-by":"publisher","unstructured":"El-mahallawy HA, El M, Abdul A, Zafer MM. Increasing trends of colistin resistance in patients at high-risk of carbapenem-resistant Enterobacteriaceae. Ann Med. 2022;54(1):2749\u201357. Available from: https:\/\/doi.org\/10.1080\/07853890.2022.2129775","DOI":"10.1080\/07853890.2022.2129775"},{"key":"11182_CR46","doi-asserted-by":"publisher","unstructured":"Zafer MM, El-Mahallawy HA, Abdulhak A, Amin MA, Al-Agamy MH, Radwan HH. Emergence of colistin resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli strains isolated from cancer patients. Ann Clin Microbiol Antimicrob. 2019;18(1):1\u20138. Available from: https:\/\/doi.org\/10.1186\/s12941-019-0339-4","DOI":"10.1186\/s12941-019-0339-4"},{"key":"11182_CR47","first-page":"80","volume":"29","author":"MM Zafer","year":"2014","unstructured":"Zafer MM, Amin M, El Mahallawy H, Ashour MSE-D, Al Agamy M. First report of NDM-1-producing Pseudomonas aeruginosa in Egypt. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2014;29:80\u20131.","journal-title":"Int J Infect Dis IJID Off Publ Int Soc Infect Dis"},{"key":"11182_CR48","doi-asserted-by":"publisher","unstructured":"Zafer MM, Maha MEB, Mona W, Amira FAH, Ramadan MA. Epidemiological Features of Nosocomial Klebsiella Pneumoniae: Virulence and Resistance Determinants. Future Microbiol. 2022;17(1):27\u201340. Available from: https:\/\/doi.org\/10.2217\/fmb-2021-0092","DOI":"10.2217\/fmb-2021-0092"},{"key":"11182_CR49","doi-asserted-by":"crossref","unstructured":"Amsalu A, Sapula SA, De Barros Lopes M, Hart BJ, Nguyen AH, Drigo B et al. Efflux Pump-Driven Antibiotic and Biocide Cross-Resistance in Pseudomonas aeruginosa Isolated from Different Ecological Niches: A Case Study in the Development of Multidrug Resistance in Environmental Hotspots. Vol. 8, Microorganisms. 2020;1647.","DOI":"10.3390\/microorganisms8111647"},{"issue":"24","key":"11182_CR50","doi-asserted-by":"publisher","first-page":"15779","DOI":"10.3390\/ijms232415779","volume":"23","author":"AB Lorusso","year":"2022","unstructured":"Lorusso AB, Carrara JA, Barroso CDN, Tuon FF, Faoro H. Role of efflux pumps on antimicrobial resistance in Pseudomonas aeruginosa. Int J Mol Sci. 2022;23(24):15779.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"11182_CR51","doi-asserted-by":"publisher","first-page":"7276","DOI":"10.1128\/AAC.01785-15","volume":"59","author":"K Poole","year":"2015","unstructured":"Poole K, Lau CH-F, Gilmour C, Hao Y, Lam JS. Polymyxin susceptibility in Pseudomonas aeruginosa linked to the MexXY-OprM multidrug efflux system. Antimicrob Agents Chemother. 2015;59(12):7276\u201389.","journal-title":"Antimicrob Agents Chemother"},{"issue":"NOV","key":"11182_CR52","first-page":"1","volume":"3","author":"Y Morita","year":"2012","unstructured":"Morita Y, Tomida J, Kawamura Y. Mexxy multidrug efflux system of Pseudomonas aeruginosa. Front Microbiol. 2012;3(NOV):1\u201313.","journal-title":"Front Microbiol"},{"key":"11182_CR53","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.2147\/IDR.S222329","volume":"12","author":"R El-Mahdy","year":"2019","unstructured":"El-Mahdy R, El-Kannishy G. Virulence factors of carbapenem-resistant pseudomonas aeruginosa in hospital-acquired infections in mansoura, Egypt. Infect Drug Resist. 2019;12:3455\u201361.","journal-title":"Infect Drug Resist"},{"key":"11182_CR54","doi-asserted-by":"publisher","unstructured":"Sharma D, Misba L, Khan AU. Antibiotics versus biofilm: an emerging battleground in microbial communities. Antimicrob Resist Infect Control. 2019;8(1):76. Available from: https:\/\/doi.org\/10.1186\/s13756-019-0533-3","DOI":"10.1186\/s13756-019-0533-3"},{"issue":"9","key":"11182_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antibiotics10091134","volume":"10","author":"M Gajd\u00e1cs","year":"2021","unstructured":"Gajd\u00e1cs M, Bar\u00e1th Z, K\u00e1rp\u00e1ti K, Szab\u00f3 D, Usai D, Zanetti S, et al. No correlation between biofilm formation, virulence factors, and antibiotic resistance in pseudomonas aeruginosa: results from a laboratory-based in vitro study. Antibiotics. 2021;10(9):1\u201316.","journal-title":"Antibiotics"},{"issue":"1","key":"11182_CR56","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4103\/mj.mj_14_21","volume":"21","author":"EH AL-Jesmany","year":"2022","unstructured":"AL-Jesmany EH, Abbas O, Hasan AlSaadi B. Molecular technology for the detection of pyoviridine gene in Pseudomonas aeruginosa isolated from burn cases. Mustansiriya Med J. 2022;21(1):23.","journal-title":"Mustansiriya Med J"},{"key":"11182_CR57","doi-asserted-by":"crossref","unstructured":"Nassar O, Desouky SE, El-Sherbiny GM, Abu-Elghait M. Correlation between phenotypic virulence traits and antibiotic resistance in Pseudomonas aeruginosa clinical isolates. Microb Pathog. 2022;162:105339. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0882401021006136","DOI":"10.1016\/j.micpath.2021.105339"},{"issue":"2","key":"11182_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/microorganisms8020260","volume":"8","author":"A Dave","year":"2020","unstructured":"Dave A, Samarth A, Karolia R, Sharma S, Karunakaran E, Partridge L, et al. Characterization of ocular clinical isolates of pseudomonas aeruginosa from non-contact lens related keratitis patients from South India. Microorganisms. 2020;8(2):1\u201314.","journal-title":"Microorganisms"},{"key":"11182_CR59","doi-asserted-by":"publisher","unstructured":"Newman JW, Floyd RV, Fothergill JL. The contribution of Pseudomonas aeruginosa virulence factors and host factors in the establishment of urinary tract infections. FEMS Microbiol Lett. 2017;364(15):fnx124. Available from: https:\/\/doi.org\/10.1093\/femsle\/fnx124","DOI":"10.1093\/femsle\/fnx124"},{"issue":"11","key":"11182_CR60","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3390\/microorganisms11051345","volume":"5","author":"T Sousa","year":"2023","unstructured":"Sousa T, De, Michel H, Alves O, Costa E, Pereira E, Martins \u00c2, et al. Study of antimicrobial resistance, biofilm formation, and motility of Pseudomonas aeruginosa derived from urine samples. Microorganisms. 2023;5(11):1345.","journal-title":"Microorganisms"},{"issue":"April","key":"11182_CR61","first-page":"1","volume":"11","author":"RF Langendonk","year":"2021","unstructured":"Langendonk RF, Neill DR, Fothergill JL. The Building blocks of antimicrobial resistance in Pseudomonas aeruginosa: implications for current resistance-Breaking therapies. Front Cell Infect Microbiol. 2021;11(April):1\u201322.","journal-title":"Front Cell Infect Microbiol"},{"issue":"November 2007","key":"11182_CR62","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1462-2920.2008.01747.x","volume":"11","author":"S Lai","year":"2009","unstructured":"Lai S, Tremblay J, D\u00e9ziel E. Swarming motility: a multicellular behaviour conferring antimicrobial resistance. Environ Microbiol. 2009;11(November 2007):126\u201336.","journal-title":"Environ Microbiol"},{"issue":"July","key":"11182_CR63","first-page":"1","volume":"8","author":"O Irazoki","year":"2017","unstructured":"Irazoki O, Campoy S, Barb\u00e9 J. The transient multidrug resistance phenotype of Salmonella enterica swarming cells is abolished by Sub-inhibitory concentrations of antimicrobial compounds. Front Microbiol. 2017;8(July):1\u201310.","journal-title":"Front Microbiol"},{"key":"11182_CR64","unstructured":"Amina M. Pseudomonas motility and antibiotics resistance. J Bioeng Biomed Sc. 2017;7:220:1\u20137."},{"issue":"8","key":"11182_CR65","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1073\/pnas.0910934107","volume":"107","author":"MT Butler","year":"2010","unstructured":"Butler MT, Wang Q, Harshey RM. Cell density and mobility protect swarming bacteria against antibiotics. Proc Natl Acad Sci. 2010;107(8):3776\u201381.","journal-title":"Proc Natl Acad Sci"},{"key":"11182_CR66","doi-asserted-by":"publisher","first-page":"127099","DOI":"10.3389\/fmicb.2023.1270999","volume":"14","author":"E Jordana-Lluch","year":"2023","unstructured":"Jordana-Lluch E, Barcel\u00f3 IM, Escobar-Salom M, Est\u00e9vez MA, Zamorano L, G\u00f3mez-Zorrilla S, et al. The balance between antibiotic resistance and fitness\/virulence in Pseudomonas aeruginosa: an update on basic knowledge and fundamental research. Front Microbiol. 2023;14:127099.","journal-title":"Front Microbiol"},{"issue":"5","key":"11182_CR67","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/j.1365-2958.2006.05306.x","volume":"61","author":"LEP Dietrich","year":"2006","unstructured":"Dietrich LEP, Price-Whelan A, Petersen A, Whiteley M, Newman DK. The phenazine pyocyanin is a terminal signalling factor in the quorum sensing network of Pseudomonas aeruginosa. Mol Microbiol. 2006;61(5):1308\u201321.","journal-title":"Mol Microbiol"},{"key":"11182_CR68","doi-asserted-by":"publisher","unstructured":"Wang F, He Q, Yin J, Xu S, Hu W, Gu L. BrlR from Pseudomonas aeruginosa is a receptor for both cyclic di-GMP and pyocyanin. Nat Commun. 2018;9(1):2563. Available from: https:\/\/doi.org\/10.1038\/s41467-018-05004-y","DOI":"10.1038\/s41467-018-05004-y"},{"key":"11182_CR69","doi-asserted-by":"publisher","unstructured":"Jessica M, Barbara C, HD E, Cristian R. The multidrug efflux pump regulator AcrR directly represses motility in Escherichia coli. mSphere. 2023;8(5):e00430-23. Available from: https:\/\/doi.org\/10.1128\/msphere.00430-23","DOI":"10.1128\/msphere.00430-23"},{"issue":"Pt 5","key":"11182_CR70","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1099\/jmm.0.017715-0","volume":"59","author":"TS Murray","year":"2010","unstructured":"Murray TS, Ledizet M, Kazmierczak BI. Swarming motility, secretion of type 3 effectors and biofilm formation phenotypes exhibited within a large cohort of Pseudomonas aeruginosa clinical isolates. J Med Microbiol. 2010;59(Pt 5):511\u201320.","journal-title":"J Med Microbiol"},{"key":"11182_CR71","doi-asserted-by":"publisher","unstructured":"Lin C-S, Tsai Y-H, Chang C-J, Tseng S-F, Wu T-R, Lu C-C et al. An iron detection system determines bacterial swarming initiation and biofilm formation. Sci Rep. 2016;6(1):36747. Available from: https:\/\/doi.org\/10.1038\/srep36747","DOI":"10.1038\/srep36747"},{"key":"11182_CR72","doi-asserted-by":"publisher","unstructured":"Frem JA, Doumat G, Kazma J, Gharamti A, Kanj SS, Abou Fayad AG et al. Clinical predictors of mortality in patients with pseudomonas aeruginosa infection. PLoS One. 2023;18(4):e0282276. Available from: https:\/\/doi.org\/10.1371\/journal.pone.0282276","DOI":"10.1371\/journal.pone.0282276"},{"key":"11182_CR73","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.2147\/IDR.S268744","volume":"13","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Li Y, Zeng J, Chang Y, Han S, Zhao J, et al. Risk factors for mortality of inpatients with Pseudomonas aeruginosa bacteremia in china: impact of resistance profile in the mortality. Infect Drug Resist. 2020;13:4115\u201323.","journal-title":"Infect Drug Resist"},{"key":"11182_CR74","doi-asserted-by":"crossref","unstructured":"Montero MM, L\u00f3pez Montesinos I, Knobel H, Molas E, Sorl\u00ed L, Siverio-Par\u00e9s A et al. Risk factors for mortality among patients with Pseudomonas aeruginosa bloodstream infections: what is the influence of XDR phenotype on outcomes?? J Clin Med. 2020;9(2).","DOI":"10.3390\/jcm9020514"},{"key":"11182_CR75","doi-asserted-by":"publisher","unstructured":"Schulert GS, Feltman H, Rabin SDP, Martin CG, Battle SE, Rello J et al. Secretion of the Toxin ExoU Is a Marker for Highly Virulent Pseudomonas aeruginosa Isolates Obtained from Patients with Hospital-Acquired Pneumonia. J Infect Dis. 2003;188(11):1695\u2013706. Available from: https:\/\/doi.org\/10.1086\/379372","DOI":"10.1086\/379372"},{"issue":"5","key":"11182_CR76","first-page":"866","volume":"12","author":"J G\u00f3mez-Mart\u00ednez","year":"2023","unstructured":"G\u00f3mez-Mart\u00ednez J, Rocha-Gracia RDC, Bello-L\u00f3pez E, Cevallos MA, Casta\u00f1eda-Lucio M, S\u00e1enz Y, et al. Comparative genomics of Pseudomonas aeruginosa strains isolated from different ecological niches. Antibiot (Basel Switzerland). 2023;12(5):866.","journal-title":"Antibiot (Basel Switzerland)"},{"issue":"12","key":"11182_CR77","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1128\/IAI.72.12.6969-6977.2004","volume":"72","author":"CM Shaver","year":"2004","unstructured":"Shaver CM, Hauser AR. Relative contributions of Pseudomonas aeruginosa exou, exos, and exot to virulence in the lung. Infect Immun. 2004;72(12):6969\u201377.","journal-title":"Infect Immun"},{"issue":"1","key":"11182_CR78","doi-asserted-by":"publisher","first-page":"10874","DOI":"10.1038\/s41598-019-47303-4","volume":"9","author":"G Horna","year":"2019","unstructured":"Horna G, Amaro C, Palacios A, Guerra H, Ruiz J. High frequency of the exoU+\/exoS\u2009+\u2009genotype associated with multidrug-resistant high-risk clones of Pseudomonas aeruginosa clinical isolates from Peruvian hospitals. Sci Rep. 2019;9(1):10874.","journal-title":"Sci Rep"},{"issue":"2","key":"11182_CR79","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/toxins14020152","volume":"14","author":"KS Hardy","year":"2022","unstructured":"Hardy KS, Tuckey AN, Renema P, Patel M, Al-Mehdi AB, Spadafora D, et al. ExoU induces lung endothelial cell damage and activates Pro-Inflammatory Caspase-1 during Pseudomonas aeruginosa infection. Toxins (Basel). 2022;14(2):152.","journal-title":"Toxins (Basel)"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11182-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11182-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11182-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:07:57Z","timestamp":1781604477000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-11182-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11182"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11182-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]},"assertion":[{"value":"31 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received approval from the Safe Handling and Disposal of Chemicals and Biologicals committee at the Faculty of Pharmacy, Cairo University, Egypt (ML2836) and the local ethical committee at the Faculty of Pharmacy, Ahram Canadian University (REC1723). The isolates were obtained from the Microbiology Lab for routine investigation and there was no direct contact with patients. Additionally, the study protocol was approved by the institutional ethics committee of the National Cancer Institute, Cairo University (Protocol No.CP1912-60301), and that all clinical data were anonymized prior to analysis to ensure patient confidentiality, in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"804"}}